# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

185,000

200M

154

Countries delivered to

Our authors are among the

**TOP 1%** 

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



# The Silver Nanoparticle (Nano-Ag): a New Model for Antifungal Agents

Juneyoung Lee, Keuk-Jun Kim, Woo Sang Sung, Jong Guk Kim and Dong Gun Lee

School of Life Sciences and Biotechnology, College of Natural Sciences, Kyungpook National University Republic of Korea

#### 1. Introduction

In recent years, a rapid increase in microbes that are resistant to conventional antibiotics has been observed (Goffeau, 2008). Especially, the frequency of infections provoked by opportunistic fungal strains has increased dramatically. Even though the majority of invasive fungal infections are still due to the *Aspergillus* or *Candida* species, the spectrum of fungal pathogens has changed and diversified (Denning, 1991; Ellis et al., 2000; Odds et al., 2003). Azoles that inhibit sterol formation and polyenes that bind to mature membrane sterols have been the mainstays regarding antifungal therapy for several decades (Kullberg & de Pauw, 1999; Sheehan et al., 1999). However, not only the emergence of fluconazole resistance among different pathogenic strains but also the high toxicity of amphotericin B (Alexander & Perfect, 1997; Mukherjee et al., 2003) has prompted research on new antifungal agents (Kontoyiannis et al., 2003).

Bio-nanotechnology has emerged as an integration between biotechnology and nanotechnology for developing biosynthesis and environmental-friendly technology for synthesis of nanomaterials. We specifically regarded nanoparticles as clusters of atoms in the size of 1-100 nm. 'Nano' is a Greek word synonymous to dwarf meaning extremely small. The use of nanoparticles is gaining impetus in the present century as they posses defined chemical, optical and mechanical properties. Among them, the metallic nanoparticles are most promising as they contain remarkable antibacterial properties due to their large surface area to volume ratio, which is of interest to researchers due to the growing microbial resistance against metal ions, antibiotics, and the development of resistant strains (Rai et al., 2009; Gong et al., 2007).

Different types of nanomaterials like copper, zinc, titanium (Schabes-Retchkiman et al., 2006), magnesium, gold (Gu et al., 2003), alginate (Ahmad et al., 2005) and silver have been developed but silver nanoparticles (Nano-Ag) have proved to be most effective as they exhibit potent antimicrobial efficacy against bacteria, viruses and eukaryotic micro-organisms. However, Nano-Ag used as a disinfectant drug also has some risks as the exposure to silver can cause argyrosis or argyria; it can be toxic to mammalian cells (Gong et al., 2007).

The current investigation supports the theory that the use of silver ions or metallic silver as well as Nano-Ag can be exploited in medicine for burn treatment, dental materials, coating stainless steel materials, textile fabrics, water treatment, sunscreen lotions, etc. and posses low toxicity to human cells, high thermal stability and low volatility (Duran et al., 2007). Many studies have shown the biological effects of Nano-Ag, however, its effects against fungal pathogens have not yet been fully studied. In this study, therefore, the antifungal properties and mechanism of actions of Nano-Ag against human pathogenic fungal strains were investigated. Furthermore, the therapeutic potential of Nano-Ag for treating fungal diseases in humans was suggested.

#### 2. Materials and methods

#### 2.1. Materials

Amphotericin B, carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), trehalase and RNase A were purchased from the Sigma Chemical Co.. Stock solutions of amphotericin B were prepared in dimethyl sulfoxide (DMSO), and stored at -20 °C. For all the experiments, a final concentration of 2% DMSO was used as the solvent carrier.

#### 2.2. Preparation of Nano-Ag

One hundred grams of solid silver were dissolved in 100 ml of 100% nitric acid at 90 °C, and then 1 l of distilled water was added. By adding sodium chloride to the silver solution, the Ag ions were precipitated and then clustered together to form monodispersed nanoparticles in the aqueous medium. The sizes and morphology of Nano-Ag were examined by using a transmission electron microscope (TEM) (H-7600, HITACHI, LTD). The result showed that the Nano-Ag was in a spherical form and had an average size of 3 nm (Fig. 1).




Fig. 1. Transmission electron micrograph (TEM) of Nano-Ag. The bar corresponds to 20 nm.

As the final concentration of colloidal silver was 60,000 ppm, this solution was diluted, and then samples of different concentrations were used to investigate the antifungal effects of Nano-Ag.

#### 2.3. Fungal strains and culture conditions

A total of 44 strains of 2 fungal species were used in this study. *Candida albicans* (ATCC 90028), *Candida glabrata* (ATCC 90030), *Candida parapsilosis* (ATCC 22019), and *Candida krusei* (ATCC 6258) were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Clinical isolates of *Candida* spp. were obtained from the Department of Laboratory Medicine, Chonnam National University Medical School (Gwangju, Korea), and clinical isolates of *Trichophyton mentagrophytes* were obtained from the Institute of Medical Mycology, Catholic Skin Clinic (Daegu, Korea). *Candida* spp. and *Trichophyton mentagrophytes* were cultures in a Sabouraud dextrose agar (SDA) and a potato dextrose agar (PDA) at 35 °C, respectively.

#### 2.4. Antifungal susceptibility testing

The minimum inhibitory concentration (MIC) for Candida spp. and T. mentagrophytes was determined by a broth microdilution method based on the National Committee for Clinical Laboratory Standards (NCCLS; now renamed as Clinical and Laboratory Standards Institute, CLSI, 2000) method outlined in documents M-27A and M-38P, respectively. An RPMI 1640 medium buffered to pH 7.0 with 3-(N-morpholino) propanesulfonic acid (MOPS) was used as the culture medium, and the inoculum size of Candida spp. was  $0.5 \times 10^3$  to  $2.5 \times 10^3$ cells/ml, and that of T. mentagrophytes was  $0.4 \times 10^4$  to  $5 \times 10^4$  cells/ml. The microdilution plates inoculated with fungi were incubated at 35 °C, and the turbidity of the growth control wells was observed every 24 hrs. The 80% inhibitory concentration (IC<sub>80</sub>) was defined as the lowest concentration that inhibited 80% of the growth as determined by a comparison with the growth in the control wells. The growth was assayed with a microplate reader (Bio-Tek Instruments, Winooski, VT, USA) by monitoring absorption at 405 nm. In the current study, amphotericin B and fluconazole were used as a positive control toward fungi; amphotericin B is a fungicidal agent widely used in treating serious systemic infections (Hartsel & Bolard, 1996), and fluconazole is used in the treatment of superficial skin infections caused by dermatophytes and Candida species (Amichai & Grunwald, 1998).

## 2.5. The effect on the dimorphic transition of C. albicans

*C. albicans* cells were maintained by periodic subculturing in a liquid yeast extract/peptone/dextrose (YPD) medium. Cultures of yeast cells (blastoconidia) were maintained in a liquid YPD medium at 37 °C. To induce mycelial formation, cultures were directly supplemented with 20% of fetal bovine serum (FBS). The dimorphic transition in *C. albicans* was investigated from cultures containing 2 mg/ml of Nano-Ag (at the IC<sub>80</sub>), which were incubated for 48 hrs at 37 °C (Jung et al., 2007; Sung et al., 2007). The dimorphic transition to mycelial forms was detected by phase contrast light microscopy (NIKON, ECLIPSE TE300, Japan).

#### 2.6. Hemolytic activity assay

The hemolytic effect of Nano-Ag was examined by measuring the release of hemoglobin from a 4% suspension of fresh human red blood cells (hRBCs). The hRBCs were washed with phosphate-buffered saline (PBS: 35 mM phosphate buffer/150 mM NaCl, pH 7.4). One-hundred microliters of hRBC suspension was added to the 96-well microtiter plates, and then 100 µl of the compound solution in PBS was mixed into each well. After incubating the mixtures for 1 hr at 37 °C, the mixtures were centrifuged at 1,500 rpm for 10 min, and the aliquots were transferred to new 96-well microtiter plates. The absorbance of the aliquots was measured at 414 nm by using a microtiter ELISA Reader. Hemolytic rates of 0 and 100% were determined in PBS and 0.1% Triton X-100, respectively (Park et al., 2003). The percentage of hemolysis was calculated by employing the following equation:

Percentage hemolysis =  $[(Abs_{414 \text{ nm}} \text{ in the compound solution - } Abs_{414 \text{ nm}} \text{ in PBS})/(Abs_{414 \text{ nm}} \text{ in 0.1\% Triton X-100 - } Abs_{414 \text{ nm}} \text{ in PBS})] x 100.$ 

#### 2.7. Flow cytometric analysis for plasma membrane potential

For analysis of the membrane integrity after the treatment of Nano-Ag, log-phased cells of *C. albicans* (1 x 108 cells), cultured in a YPD medium, were harvested and resuspended with 1 ml of a fresh YPD medium, containing 30  $\mu$ g/ml of Nano-Ag (at 15 times the MIC) or 10  $\mu$ M of CCCP, used as a positive control. After incubation for 3 hrs, the cells were washed three times with PBS. To detect any depolarization of the cell membrane, 1 ml of PBS, containing 50  $\mu$ g of bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)], was added and the samples were incubated for 1 hr at 4°C in the dark (Liao et al., 1999). Flow cytometric analysis was performed using a FACSCalibur flow cytometer.

#### 2.8. Measurement of plasma membrane fluorescence intensity

The fluorescence intensity from exponential *C. albicans* cells labeled by 1,6-diphenyl-1,3,5-hexatriene (DPH) was used to monitor changes in membrane dynamics. The cells (1 x 108 cells in a YPD medium), containing 20, 40, 60 and 80  $\mu$ g/ml of Nano-Ag or amphotericin B, were incubated at a physiological temperature of 28°C on a rotary shaker at 140 rpm for 2 hrs. The control cells were incubated without a compound. The cells were fixed with formaldehyde (0.37%, v/v) for 45 min and they were collected by centrifugation at 3,000 rpm, then washed several times with PBS buffer (pH 7.4), and the pellets were frozen in liquid nitrogen. For DPH labeling, the pellets were resuspended in PBS buffer and incubated at 28°C for 45 min in the presence of 0.6 mM of DPH, followed by several washings in PBS buffer. The steady-state fluorescence intensity was measured by using a SHIMADZU RF-5301PC spectrofluorophotometer at 350 nm excitation and 425 nm emission wavelengths (Fernandes et al., 2000). The results represent the average of the triplicate measurements from three independent assays.

#### 2.9. Determining released glucose and trehalose

Fungal strains were grown at 28°C in a YPD medium. *C. albicans* cells were washed three times with PBS, and then 1 ml of the *C. albicans* cell suspension (1 x  $10^8$  cells), containing 20  $\mu$ g/ml of Nano-Ag (at 20 times the MIC), was incubated for 2 hrs at 28°C in PBS. The negative control was incubated without Nano-Ag, and a positive control was incubated

with 100  $\mu$ g/ml of amphotericin B (at 20 times the MIC). The fungal cells were settled by centrifugation (12,000 rpm for 20 min). The pellets were dried to calculate their dry weight and supernatants were transferred to a new tube. Released glucose and trehalose-containing supernatants were added to 0.05 units of trehalase. After 1 hr of enzymatic reaction at 37°C, the reaction suspension was mixed with water and 16% DNS reagent (3,5-dinitrosalicylic acid 1%, NaOH 2%, sodium potassium tartrate 20%) was added. For the reaction of glucose with the DNS reagent, the mixture was boiled for 5 min and cooled. Color formations were measured at 525 nm. The results represent the average of the measurements conducted in triplicate of three independent assays.

#### 2.10. Transmission electron microscopy (TEM)

Log-phased cells of *C. albicans* (1 x 10<sup>8</sup> cells) cultured in a YPD medium, were harvested and incubated in the presence of several different amounts of Nano-Ag for 24 hrs at 28°C. TEM was used as a complementary technique to examine sections of the treated cells, using standard procedures for fixing and embedding sensitive biological samples, which are described elsewhere (Osumi, 1998; Mares et al., 1998).

#### 2.11. Flow cytometric analysis for a fungal cell cycle

Log-phased cells of *C. albicans* (1 x 10<sup>8</sup> cells) cultured in a YPD medium, were harvested and treated with 40  $\mu$ g/ml of Nano-Ag (at 20 times the MIC). After incubation for 8 hrs, the cells were washed with PBS and fixed with 70% ethanol overnight at 4°C. The cells were treated with 200  $\mu$ g/ml of RNase A and the mixture was left to react for 2 hrs at 37°C. For DNA staining, 50  $\mu$ g/ml of propidium iodide (PI) were added and incubated for 1 hr at 4°C in the dark (Green et al., 1999). Flow cytometric analysis was performed by a FACSCalibur flow cytometer. The values represent the average of the measurements conducted in triplicate of three independent assays.

#### 3. Results and discussion

#### 3.1. Antifungal activity of Nano-Ag

In the past, silver has been in use for the treatment of burns or chronic wounds. In the 1940s, however, after penicillin was introduced, the use of silver for the treatment of bacterial infections decreased (Hugo & Russell, 1982; Demling & DeSanti, 2001; Chopra, 2007). Silver again came in picture in the 1960s when Moyer introduced the use of 0.5% silver nitrate for the treatment of burns. He proposed that this solution does not interfere with epidermal proliferation and possess antibacterial properties against *Staphylococcus aureus*, *Pseudomonas aeruginosa and Escherichia coli* (Moyer et al., 1965; Bellinger & Conway, 1970). In 1968, silver nitrate was combined with sulfonamide to form silver sulfadazine cream, which served as a broad-spectrum antibacterial agent and was used for the treatment of burns. Silver sulfadazine is effective against various bacterial strains like *E. coli*, *S. aureus*, *Klebsiella* sp., and *Pseudomonas* sp. (Rai et al., 2009). It also possesses some antifungal and antiviral activities (Fox & Modak, 1974). Recently, due to the emergence of antiobiotic-resistant bacteria and limitations of the use of antibiotics clinicians have returned to using silver wound dressings, containing varying level of silver (Gemmell et al., 2006; Chopra, 2007). For

these reasons, the antifungal activity and its mechanism of silver, Nano-Ag specifically, was investigated.

Nano-Ag, in an IC<sub>80</sub> range of 1-25  $\mu$ g/ml, showed significant antifungal activity against *T. mentagrophytes* and *Candida* species. Toward all fungal strains, Nano-Ag exhibited similar activity with amphotericin B, showing IC<sub>80</sub> values of 1-5  $\mu$ g/ml, but more potent activity than fluconazole, showing IC<sub>80</sub> values of 10-30  $\mu$ g/ml. However, this compound exhibited less potent activity than amphotericin B, showing IC<sub>80</sub> values of 2-4  $\mu$ g/ml for *C. parapsilosis* and *C. krusei* (Table 1).

Fungal strains	IC <sub>80</sub> (μg/ml)		
(no. of strains)	Nano-Ag	Amphotericin B	Fluconazole
C. albicans (4)	2-4	5	10-16
C. tropicalis (2)	7	2-4	13
C. glabrata (4)	1-7	2	10-16
C. parapsilosis (3)	4-25	2	13
C. krusei (1)	13	4	13
T. mentagrophytes (30)	1-4	1-2	20-30

Table 1. Antifungal activity of Nano-Ag.

In order to elucidate the antifungal activity of Nano-Ag, the dimorphic transition of *C. albicans*, induced by Nano-Ag, was investigated. The dimorphic transition of *C. albicans* from yeast form to mycelial form is responsible for pathogenicity, with mycelial shapes being predominantly found during the invasion of host tissue. A mycelial form can be induced by temperature, pH, and serum (McLain et al., 2000). As shown in Fig. 2, the serum-induced mycelia were significantly inhibited from extending and forming in the presence of Nano-Ag (Fig. 2C), but the mycelia formed was normal in the absence of Nano-Ag (Fig. 2B).




Fig. 2. The effect of Nano-Ag on the dimorphic transition in *C. albicans*. (A) Yeast control without 20% FBS and Nano-Ag, (B) Cells treated with only 20% FBS, (C) Cells treated with 2 µg/ml of Nano-Ag.

These results confirmed the antifungal activity of Nano-Ag and suggested that Nano-Ag can be a potential compound in the treatment of fungal infectious diseases.

#### 3.2. Hemolytic activity of Nano-Ag against human erythrocytes

Many antimicrobial agents are limited regarding clinical applications, as they can induce cytolysis of human cells. The hemolytic activity of Nano-Ag was investigated as an indicator

of its cytotoxicity to mammalian cells. The hemolytic activity was evaluated by the percentage of hemolysis in the concentration range of 1.25-10  $\mu$ g/ml. The result showed that Nano-Ag caused 6% lysis of erythrocytes at a concentration of 10  $\mu$ g/ml, whereas amphotericin B induced 10% lysis at the same level (Table 2).

Compound	% Hemolysis (µg/ml)				
Compound -	10	5	2.5	1.25	
Nano-Ag	6	0	0	0	
Amphotericin B	10	0	0	0	

Table 2. Hemolytic activity of Nano-Ag against human erythrocytes.

This result suggested that Nano-Ag could be applied to therapeutic agents regarding human fungal diseases with low cytotoxicity.

### 3.3. Changes of plasma membrane potential induced by Nano-Ag

To assess whether Nano-Ag can affect the function of a fungal plasma membrane, the dissipation of the fungal plasma membrane potential was investigated. *C. albicans* cells were cultured in the presence of Nano-Ag or CCCP used as a positive control, and the amounts of accumulated DiBAC<sub>4</sub>(3) in the cells were measured *via* flow cytometry by staining with DiBAC<sub>4</sub>(3). CCCP is an H<sup>+</sup> ionophore which dissipates the H<sup>+</sup> gradient and thus uncouples electron transport from ATP synthesis (Ghoul et al., 1989). DiBAC<sub>4</sub>(3) has a high voltage sensitivity and it enters depolarized cells, where it binds to lipid-rich intracellular components (Liao et al., 1999). Therefore, the fluorescence of DiBAC<sub>4</sub>(3) increases upon membrane depolarization. The addition of Nano-Ag to *C. albicans* cells caused an increase in fluorescence intensity, similar to the increase observed in the presence of CCCP, which is indicative of membrane depolarization (Fig. 3). This result indicated that Nano-Ag affected yeast cells by attacking their membranes, thus disrupting membrane potential.




Fig. 3. FACScan analysis of DiBAC<sub>4</sub>(3) staining in *C. albicans*. *C. albicans* were mixed with 30  $\mu$ g/ml of Nano-Ag and 10  $\mu$ M of CCCP and incubated at 28 °C for 3 hrs under constant shaking. This figure shows the fluorescence intensity of stained *C. albicans* treated with the

compounds. FL2-H indicates the log fluorescent intensity of DiBAC<sub>4</sub>(3), and y-axis indicates cell numbers (events).

#### 3.4. Changes in the plasma membrane dynamics of fungal cells induced by Nano-Ag

The effect of Nano-Ag on the fungal plasma membrane was further investigated by using DPH as a membrane probe. If the antifungal activities exerted by Nano-Ag on *C. albicans* are at the level of the cell plasma membrane, DPH, which can interact with an acyl group of the plasma membrane lipid bilayer, can not be inserted into the membrane. As shown in Fig. 4, the plasma membrane DPH fluorescence anisotropy was significantly decreased by increasing the concentrations of Nano-Ag or amphotericin B. This is consistent with the disruption of the plasma membrane by Nano-Ag as well as by a positive control, amphotericin B.




Fig. 4. DPH fluorescence anisotropy after the addition of Nano-Ag or amphotericin B. The error bars represent the standard deviation (SD) values for three independent experiments, performed in triplicate.

#### 3.5. Intracellular glucose and trehalose release induced by Nano-Ag

The ability of Nano-Ag to disturb the integrity of the plasma membrane of fungal cells was also assessed by measuring the glucose and trehalose released in cell suspensions which were exposed to this compound. Trehalose can protect proteins and biological membranes from inactivation or denaturation caused by a variety of stress conditions, including desiccation, dehydration, heat, cold, oxidation, and toxic agents in yeast (Alvarez-Peral et al., 2002; Elbein et al., 2003). The result showed that Nano-Ag or amphotericin B-treated cells both accumulated more intracellular glucose and trehalose than the compound-untreated cells. In addition, these cells also increased extracellular glucose and trehalose than the


compound-untreated cells. The extracellular glucose and trehalose, induced by amphotericin B, were measured as being 27.4  $\mu g$  per fungal dry weight of 1 mg. The extracellular glucose and trehalose amounts, however, induced by Nano-Ag were measured as being 30.3  $\mu g$  per fungal dry weight of 1 mg. This rate was significantly higher than that induced in the compound-untreated cells (Table 3). The result suggests that it may be one of several intracellular components released during membrane disruption by Nano-Ag. As for the mechanism by which Nano-Ag breaks down the membrane permeability barrier, it is possible that Nano-Ag perturbs the membrane lipid bilayers, causing the leakage of ions and other materials as well as forming pores and dissipating the electrical potential of the membrane.

	Amounts of trehalose and glucose			
	concentrations (μg/mg)			
	Intracellular glucose	Released glucose and		
	and trehalose	trehalose		
Control	7.2	6.8		
Nano-Ag	16.1	30.3		
Amphotericin B	20.5	27.4		

Table 3. The concentrations of trehalose and glucose from *C. albicans* by Nano-Ag and amphotericin B.

#### 3.6. Transmission electron microscopic (TEM) analysis

TEM was used to evaluate the ability of Nano-Ag to disrupt the fungal envelope structure. The results showed that the Nano-Ag-treated fungal cells showed significant damage, which was characterized by the formation of a "pit" in their cell walls and pores in their plasma membrane (Fig. 5).






Fig. 5. Transmission electron micrograph (TEM) of *C. albicans* cells. *C. albicans* were incubated in the presence of different amounts of Nano-Ag for 24 hrs at 28 °C. The bar marker represents 1  $\mu$ m. (A) Control, (B) Cells treated with 170  $\mu$ g/ml of Nano-Ag, (C) Cells treated with 400  $\mu$ g/ml of Nano-Ag.

# 3.7. The arrest of fungal cell cycle induced by Nano-Ag

In order to elucidate the physiological changes of the fungal cells induced by Nano-Ag, a flow cytometric analysis of the cell cycle was performed. The cells were cultured in the presence or absence of Nano-Ag and their DNA content was determined via flow cytometry by staining with propidium iodide (PI). PI is a DNA-staining dye that intercalates between the bases of DNA or RNA molecules (Tas & Westerneng, 1981). As shown in Fig. 6, the percentage of cells in the  $G_2/M$  phase increased by 15%, while that in the  $G_1$  phase significantly decreased by about 20% in the presence of Nano-Ag. This data suggests that Nano-Ag inhibited some cellular processes which are involved in normal bud growth. Endo et al. have reported that the inhibition of bud growth correlates with membrane damage

(Endo et al., 1997). Therefore, this report suggests that Nano-Ag inhibits the normal budding process, probably through the destruction of membrane integrity.




Fig. 6. The effects of Nano-Ag on the process of the cell cycle of *C. albicans*. *C. albicans* were incubated in the presence of Nano-Ag for 8 hrs at 28  $^{\circ}$ C. FL2-H indicates the fluorescent intensity of PI, and y-axis indicates cell numbers (events). (A) FACS diagram of cell cycle; (a) Control without Nano-Ag, (b) Cells treated with 40  $\mu$ g/ml Nano-Ag, (B) A histogram indicating the percentage of each cell cycle progress.

#### 4. Conclusion

Many studies have shown the antimicrobial effects of Nano-Ag (Klasen, 2000; Russell & Hugo, 1994; Silver, 2003), but the effects of Nano-Ag against fungal pathogens of the skin, including clinical isolates of *T. mentagrophytes* and *Candida* species are mostly unknown. The primary significance of this study is the observation that Nano-Ag can inhibit the growth of dermatophytes, which cause superficial fungal infections (Kim et al., 2008). Nano-Ag also exhibited potent antifungal effects, probably through destruction of membrane integrity (Kim et al., 2009). To the author's knowledge, this is the first study to apply Nano-Ag successfully to dermatophytes and pathogenic fungal strains. Secondly, the fact that preparation method of Nano-Ag described here is cost-effective is also of importance. Therefore, it can be expected that Nano-Ag may have potential as an anti-infective agent for human fungal diseases.

# 5. References

Ahmad, Z.; Pandey, R.; Sharma, S. & Khuller, G.K. (2006). Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. *Indian journal of chest diseases and allied sciences*, Vol. 48, No. 3, (July-September) 171-176, ISSN 0377-9343

Alexander, B.D. & Perfect, J.R. (1997). Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. *Drugs*, Vol. 54, No. 5, (November) 657-678, ISSN 0012-6667

Alvarez-Peral, F.J.; Zaragoza, O.; Pedreno, Y. & Argüelles, J.C. (2002). Protective role of trehalose during severe oxidative stress caused by hydrogen peroxide and the adaptive oxidative stress response in *Candida albicans*. *Microbiology*, Vol. 148, No. Pt 8, (August) 2599-2606, ISSN 1350-0872


- Amichai, B. & Grunwald, M.H. (1998). Adverse drug reactions of the new oral antifungal agents—terbinafine, fluconazole, and itraconazole. *International journal of dermatology*, Vol. 37, No. 6, (June) 410-415, ISSN 0011-9059
- Bellinger, C.G. & Conway, H. (1970). Effects of silver nitrate and sulfamylon on epithelial regeneration. *Plastic and reconstructive surgery*, Vol. 45, No. 6, (June) 582-585, ISSN 0032-1052
- Chopra, I. (2007). The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?. *Journal of antimicrobial chemotherapy*, Vol. 59, No. 4, (April) 587-590, ISSN 0305-7453
- Demling, R.H. & DeSanti, L. (2001). Effects of silver on wound management. *Wounds*, Vol. 13, No. Suppl A, 5-15, ISSN 1044-7946
- Denning, D.W. (1991). Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host, Journal of antimicrobial chemotherapy, Vol. 28, No. Suppl B, (October) 1-16, ISSN 0305-7453.
- Durán, N.; Marcarto, P.D.; De Souza, G.I.H.; Alves, O.L. & Esposito, E. (2007). Antibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. *Journal of biomedical nanotechnology*, Vol. 3, No. 2, (June) 203-208, ISSN 1550-7033
- Elbein, A.D.; Pan, Y.T.; Pastuszak, I. & Carroll, D. (2003). New insights on trehalose: a multifunctional molecule. *Glycobiology*, Vol. 13, No. 4, (April) 17R-27R, ISSN 0959-6658
- Ellis, M.; Richardson, M. & de Pauw, B. (2000). Epidemiology. *Hospital medicine*, Vol. 61, No. 9, (September) 605-609, ISSN 1462-3935
- Endo, M.; Takesako, K.; Kato, I. & Yamaguchi, H. (1997). Fungicidal action of aureobasidin A, a cyclic depsipeptide antifungal antibiotic, against *Saccharomyces cerevisiae*. *Antimicrobial agents and chemotherapy*, Vol. 41, No. 3, (March) 672-676, ISSN 0066-4804
- Fernandes, A.R.; Prieto, M. & Sá-Correia, I. (2000). Modification of plasma membrane lipid order and H+-ATPase activity as part of the response of Saccharomyces cerevisiae to cultivation under mild and high copper stress. *Archives of microbiology*, Vol. 173, No. 4, (April) 262-268, ISSN 0302-8933
- Fox, C.L.Jr. & Modak, S.M. (1974). Mechanism of silver sulfadiazine action on burn wound infections. *Antimicrobial agents and chemotherapy*, Vol. 5, No. 6, (June) 582-588, ISSN 0066-4804
- Gemmell, C.G.; Edwards, D.I.; Fraise, A.P.; Gould, F.K.; Ridgway, G.L. & Warren, R.E. (2006). Guidelines for the prophylaxis and treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the UK. *Journal of antimicrobial chemotherapy*, Vol. 57, No. 4, (April) 589-608, ISSN 0305-7453
- Ghoul, M.; Pommepuy, M.; Moillo-Batt, A. & Cormier, M. (1989). Effect of carbonyl cyanide m-chlorophenylhydrazone on *Escherichia coli* halotolerance. *Applied and environmental microbiology*, Vol. 55, No. 4, (April) 1040-1043, ISSN 0099-2240

- Goffeau, A. (2008). Drug resistance: the fight against fungi. *Nature*, Vol. 452, No. 7187, (April) 541-542, ISSN 0028-0836
- Gong, P.; Li, H.; He, X.; Wang, K.; Hu, J.; Zhang, S. & Yang, X. (2007). Preparation and antibacterial activity of Fe<sub>3</sub>O<sub>4</sub>@Ag nanoparticles. *Nanotechnology*, Vol. 18, No. 28, (June) 604-611, ISSN 0957-4484
- Green, L.J.; Marder, P.; Mann, L.L.; Chio, L.C. & Current, W.L. (1999). LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. *Antimicrobial agents and chemotherapy*, Vol. 43, No. 4, (April) 830-835, ISSN 0066-4804
- Gu, H.; Ho, P.L.; Tong, E.; Wang, L. & Xu, B. (2003). Presenting vancomycin on nanoparticles to enhance antimicrobial activities. *Nano letters*, Vol. 3, No. 9, (August) 1261-1263, ISSN 1530-6984
- Hartsel, S. & Bolard, J. (1996). Amphotericin B: new life for an old drug. *Trends in pharmacological sciences*, Vol. 17, No. 12, (December) 445-449, ISSN 0165-6147
- Hugo, W.B. & Russell, A.D. (1982). Principles and practice of disinfection, preservation and sterilization, Oxford, ISBN 0632041943, London
- Jung, H.J.; Seu, Y.B. & Lee, D.G. (2007). Candicidal action of resveratrol isolated from grapes on human pathogenic yeast *C. albicans. Journal of microbiology and biotechnology*, Vol. 17, No. 8, (August) 1324-1329, ISSN 1017-7825
- Kim, K.J.; Sung, W.S.; Moon, S.K.; Choi, J.S.; Kim, J.G. & Lee, D.G. (2008). Antifungal effect of silver nanoparticles on dermatophytes. Journal of microbiology and biotechnology, Vol. 18, No. 8, (August) 1482-1484, ISSN 1017-7825
- Kim, K.J.; Sung, W.S.; Suh, B.K.; Moon, S.K.; Choi, J.S.; Kim, J.G. & Lee, D.G. (2009). Antifungal activity and mode of action of silver nano-particles on *Candida albicans*. *Biometals*, Vol. 22, No. 2, (April) 235-242, ISSN 0966-0844
- Klasen, H.J. (2000). A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. *Burns*, Vol. 26, No. 2, (May) 131-138, ISSN 0305-4179
- Kontoyiannis, D.P.; Mantadakis, E. & Samonis, G. (2003). Systemic mycoses in the immunocompromised host: an update in antifungal therapy. *Journal of hospital infection*, Vol. 53, No. 4, (April) 243-258, ISSN 0195-6701
- Kullberg, B.J. & de Pauw, B.E. (1999). Therapy of invasive fungal infections. *Netherlands journal of medicine*, Vol. 55, No. 3, (September) 118-127, ISSN 0300-2977
- Liao, R.S.; Rennie, R.P. & Talbot, J.A. (1999). Assessment of the effect of amphotericin B on the vitality of *Candida albicans*. *Antimicrobial agents and chemotherapy*, Vol. 43, No. 5, (May) 1034-1041, ISSN 0066-4804
- Mares, D.; Romagnoli, C.; Sacchetti, G.; Vicentini, C.B. & Bruni, A. (1998). Morphological study of *Trichophyton rubrum*: ultrastructural findings after treatment with 4-amino-3-methyl-1-phenylpyrazolo-(3,4-c)isothiazole. *Medical mycology*, Vol. 36, No. 6, (December) 379-385, ISSN 1369-3786
- McLain, N.; Ascanio, R.; Baker, C.; Strohaver, R.A. & Dolan, J.W. (2000). Undecylenic acid inhibits morphogenesis of *Candida albicans*. *Antimicrobial agents and chemotherapy*, Vol. 44, No. 10, (October) 2873-2875, ISSN 0066-4804
- Moyer, C.A.; Brentano, L.; Gravens, D.L.; Margraf, H.W. & Monafo, W.W.Jr. (1965). Treatment of large human burns with 0.5 percent silver nitrate solution. *Archives of surgery*, Vol. 90, (June) 812-867, ISSN 0272-5533

Mukherjee, P.K.; Chandra, J.; Kuhn, D.M. & Ghannoum, M.A. (2003). Mechanism of fluconazole resistance in *Candida albicans* biofilms: phase-specific role of efflux pumps and membrane sterols. *Infection and immunity*, Vol. 71, No. 8, (August) 4333-4340, ISSN 0019-9567

- Odds, F.C.; Brown, A.J. & Gow, N.A. (2003). Antifungal agents: mechanisms of action. *Trends in microbiology*, Vol. 11, No. 6, (June) 272-279, ISSN 0966-842X
- Osumi, M. (1998). The ultrastructure of yeast: cell wall structure and formation. *Micron*, Vol. 29, No. 2-3, (April-June) 207-233, ISSN 0968-4328
- Park, Y.; Lee, D.G.; Jang, S.H.; Woo, E.R.; Jeong, H.G.; Choi, C.H. & Hahm, K.S. (2003). A Leu-Lys-rich antimicrobial peptide: activity and mechanism. *Biochimica et biophysica acta*, Vol. 1645, No. 2, (February) 172-182, ISSN 0006-3002
- Rai, M.; Yadav, A. & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology advances*, Vol. 27, No. 1, (January-February) 76-83, ISSN 0734-9750
- Russell, A.D. & Hugo, W.B. (1994). Antimicrobial activity and action of silver. *Progress in medicinal chemistry*, Vol. 31, 351-370, ISSN 0079-6468
- Schabes-Retchkiman, P.S.; Canizal, G.; Herrera-Becerra, R.; Zorrilla, C.; Liu, H.B. & Ascencio, J.A. (2006). Biosynthesis and characterization of Ti/Ni bimetallic nanoparticles. *Optical materials*, Vol. 29, No. 1, (October) 95-99, ISSN 0925-3467
- Sheehan, D.J.; Hitchcock, C.A. & Sibley, C.M. (1999). Current and emerging azole antifungal agents. *Clinical microbiology reviews*, Vol. 12, No. 1, (January) 40-79, ISSN 0893-8512
- Silver, S. (2003). Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. *FEMS microbiology reviews*, Vol. 27, No. 2-3, (June) 341-353, ISSN 0168-6445
- Sung, W.S.; Lee, I.S. & Lee, D.G. (2007). Damage to the cytoplasmic membrane and cell death caused by lycopene in *Candida albicans*. *Journal of microbiology and biotechnology*, Vol. 17, No. 11, (November) 1797-1804, ISSN 1017-7825
- Tas, J. & Westerneng, G. (1981). Fundamental aspects of the interaction of propidium diiodide with nuclei acids studied in a model system of polyacrylamide films. *Journal of histochemistry and cytochemistry*, Vol. 29, No. 8, (August) 929-936, ISSN 0022-1554





Edited by David Pozo Perez

ISBN 978-953-307-028-5 Hard cover, 334 pages Publisher InTech Published online 01, March, 2010 Published in print edition March, 2010

Nanotechnology will be soon required in most engineering and science curricula. It cannot be questioned that cutting-edge applications based on nanoscience are having a considerable impact in nearly all fields of research, from basic to more problem-solving scientific enterprises. In this sense, books like "Silver Nanoparticles" aim at filling the gaps for comprehensive information to help both newcomers and experts, in a particular fast-growing area of research. Besides, one of the key features of this book is that it could serve both academia and industry. "Silver nanoparticles" is a collection of eighteen chapters written by experts in their respective fields. These reviews are representative of the current research areas within silver nanoparticle nanoscience and nanotechnology.

#### How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Juneyoung Lee, Keuk-Jun Kim, Woo Sang Sung, Jong Guk Kim and Dong Gun Lee (2010). The Silver Nanoparticle (Nano-Ag): a New Model for Antifungal Agents, Silver Nanoparticles, David Pozo Perez (Ed.), ISBN: 978-953-307-028-5, InTech, Available from: http://www.intechopen.com/books/silver-nanoparticles/the-silver-nanoparticle-nano-ag-a-new-model-for-antifungal-agents



#### InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447

Fax: +385 (51) 686 166 www.intechopen.com

#### InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元

Phone: +86-21-62489820 Fax: +86-21-62489821 © 2010 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the <u>Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License</u>, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.



